TONOPAH, Nev., Sept. 17, 2026 /PRNewswire/ -- A2Gold Corp. ("A2Gold" or the "Company") (TSXV: AUAU) (OTCQX: AUXXF) (FRA: RR7) is pleased to announce assay results from the first phase of reverse circulation ("RC") drilling completed at the McIntosh Target, part of the Company's district-scale Eastside Gold-Silver Project in Esmeralda County, Nevada, within the Walker Lane Trend.

ES-347 intersected 0.23 g/t gold over 65.5 metres beginning at 253.0 metres downhole, representing the discovery of a new zone of gold mineralization approximately 370 metres southwest of the current McIntosh resource.

ES-342 intersected 0.20 g/t gold over 32.0 metres beginning at 214.9 metres downhole, representing an 86-meter extension of known McIntosh mineralization and providing a compelling target for mineralization extension.

The new discovery in ES-347 is associated with a ~1.5 km-long but previously untested north- to northwest-oriented magnetic low anomaly.

Gold mineralization in both ES-347 and ES-342 occurs primarily along the margins of magnetic low anomalies, consistent with the geophysical relationships observed within the existing McIntosh resource.

The results provide additional support for the Company's use of integrated geophysics and geology to target mineralization outside the existing McIntosh resource footprint.

Peter Gianulis, CEO of A2Gold, commented: "The Phase 1 South McIntosh program accomplished two important objectives: it extended mineralization beyond the existing resource boundary and identified gold mineralization associated with a previously untested geophysical target southwest of McIntosh. While additional drilling will be required to understand the scale and continuity of this new zone, the results provide useful confirmation that the magnetic features surrounding McIntosh can help us identify additional mineralized structures. This work is contributing to our broader targeting strategy across the Eastside district."

McIntosh RC Drilling Results The first phase of RC drilling was designed to evaluate opportunities for resource expansion while testing high-priority geophysical targets adjacent to the existing McIntosh resource.

Hole ES-347 intersected 0.23 g/t gold over 65.5 metres beginning at 253.0 metres downhole, representing the discovery of a new zone of gold mineralization approximately 370 metres southwest of the current McIntosh resource. ES-347 represents the first drill test to intersect gold mineralization associated with a ~1.5 km north- to northwest-trending magnetic low anomaly identified in recently collected geophysical data.

Hole ES-342 intersected 0.20 g/t gold over 32.0 metres beginning at 214.9 metres downhole, extending known gold mineralization approximately 86 metres southeast of the current McIntosh resource. The intercept demonstrates that mineralization continues beyond the existing resource boundary and provides a target for additional drilling southeast of McIntosh.

Table Notes: Reported drill intercepts were calculated using a 0.10 g/t Au cut-off grade with a maximum of 5.0 metres of consecutive internal dilution. No limit was applied to the total amount of non-consecutive internal dilution included within a composite. All reported intercepts begin and end with assays above the cut-off grade. Composite intervals were calculated using uncapped raw assay values. Reported intervals represent downhole drilled lengths; true widths have not yet been determined.

Geological Significance The new gold mineralization identified in ES-347 is spatially associated with a previously untested, prominent magnetic low anomaly. Geological interpretation indicates that gold mineralization occurs primarily along the margin of the magnetic low, a relationship that closely mirrors the mineralization pattern previously identified within the existing McIntosh resource.

The similarity between the geophysical setting of ES-347 and mineralization at McIntosh suggests that magnetic-low margins may provide an effective targeting tool for identifying additional mineralized structures across the broader Eastside district. The magnetic feature associated with ES-347 remains largely untested and provides additional targets for future drilling.

Exploration Potential The first phase of RC drilling supports A2Gold's broader Eastside exploration strategy of expanding known mineralization while also testing structural and geophysical targets that may represent higher-grade feeder zones within the broader epithermal system.

The southeast extension intersected in hole ES-342 demonstrates continued potential to expand mineralization adjacent to the existing McIntosh deposit, while the new mineralized zone in ES-347 provides an additional target for future follow-up drilling. These results will also help guide the Company's ongoing evaluation and prioritization of structural targets across the broader Eastside district.

Future drilling at McIntosh will be prioritized alongside other Eastside targets based on geological interpretation, geophysical targeting and the potential to identify higher-grade mineralized structures.

Quality Assurance / Quality Control The RC drilling program included the routine insertion of certified reference materials, blanks, and field duplicates as part of the Company's quality assurance and quality control ("QA/QC") procedures. Drill samples were submitted to American Assay Laboratories in Reno, Nevada, an ISO/IEC 17025 accredited analytical laboratory. Gold analyses were completed using a 30-gram fire assay with an OES (optical emission spectrometry) finish. Samples exceeding the laboratory's upper detection limit are reanalyzed using gravimetric methods.

Qualified Person John Marma, CPG, a Certified Professional Geologist with the American Institute of Professional Geologists and a Qualified Person as defined by National Instrument 43-101, has reviewed and approved the scientific and technical information contained in this news release.

About A2Gold Corp A2Gold Corp. has built a multi-asset gold-silver exploration platform in Nevada, one of the world's premier mining jurisdictions. The Company controls approximately 230 km² of prospective mineral tenure across its Eastside and Taylor projects, both district-scale assets with large precious metals resources with significant exploration and resource growth potential.

Eastside hosts an inferred mineral resource of 1.4 million ounces of gold and 8.8 million ounces of silver*, while Taylor adds a highly prospective exploration district with gold, silver, antimony and porphyry-skarn upside. Backed by a fully funded exploration program and a strong pipeline of catalysts, A2Gold is focused on unlocking value through resource expansion, new discoveries and systematic district-scale exploration.

A2Gold is also supported by a strong shareholder base, including Kinross Gold Corporation, which owns approximately 9.9% of the Company's issued and outstanding shares.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements and information contained in this press release constitute "forward-looking statements" within the meaning of applicable U.S. securities laws and "forward-looking information" within the meaning of applicable Canadian securities laws, which are referred to collectively as "forward-looking statements". The United States Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. A2Gold Corp.'s ("A2Gold") exploration plans for its gold exploration properties, the drill program at A2Gold's Eastside project, the preparation and publication of an updated resource estimate in respect of the Original Zone at the Eastside project, A2Gold's future exploration and development plans, including anticipated costs and timing thereof; A2Gold's plans for growth through exploration activities, acquisitions or otherwise; and expectations regarding future maintenance and capital expenditures, and working capital requirements. Forward-looking statements are statements and information regarding possible events, conditions or results of operations that are based upon assumptions about future economic conditions and courses of action. All statements and information other than statements of historical fact may be forward-looking statements. In some cases, forward-looking statements can be identified by the use of words such as "seek", "expect", "anticipate", "budget", "plan", "estimate", "continue", "forecast", "intend", "believe", "predict", "potential", "target", "may", "could", "would", "might", "will" and similar words or phrases (including negative variations) suggesting future outcomes or statements regarding an outlook. Such forward-looking statements are based on a number of material factors and assumptions and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or industry results, to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on forward-looking statements contained in this press release. Some of the known risks and other factors which could cause actual results to differ materially from those expressed in the forward-looking statements are described in the sections entitled "Risk Factors" in A2Gold's Listing Application, dated January 24, 2018, as filed with the TSX Venture Exchange and available on SEDAR under A2Gold's profile at www.sedar.com. Actual results and future events could differ materially from those anticipated in such statements.

LONDON, Sept. 17, 2026 /PRNewswire/ -- UK startup Eterna Regeneratives has closed a seed investment round led by Hoxton Ventures and The Venture Collective (TVC) to build its regenerative biomaterial platform spanning enamel repair and bone regeneration, starting with the $43bn global oral care market. Co-founded by Khaled Eissa and Dr Sherif Elsharkawy in 2024, the King's College London spin-out attracted international attention last year when studies found the team's revolutionary patented material could successfully regrow damaged tooth enamel using keratin - a protein found in human hair, skin and wool. The research developed by Dr Elsharkawy and Dr Sara Gamea, his PhD student, was picked up widely by national and international media, including from the BBC, Washington Post and Newsweek, putting keratin-based regeneration on the map well before a commercial product existed.

Now working to develop a pipeline of material technologies, Eterna aims to tackle a problem that affects nearly everyone: the slow, irreversible loss of tooth enamel. The team at Eterna Regeneratives believes that symptom management cannot be the only solution. "The only way to truly heal the human body is to help it heal itself," said Khaled Eissa, co-founder and CEO. "We wanted to create a product that is readily available, scalable and has the potential to deliver long-term results." "This investment lets us move from lab-based proof of concept to real-world products at pace," said Dr Sherif Elsharkawy, Chief Scientific Officer and co-founder. "It is a validation of years of research, and a step change in how quickly we can bring this technology to patients."

Unlike many other tissues in the human body, tooth enamel cannot naturally regenerate once it has been lost. This can lead to hypersensitivity, cavities, tooth pain and the gradual deterioration of teeth. Fluoride, the best option currently available on the market, only superficially addresses the problem – offering minor strengthening of existing enamel but failing to rebuild what has already been lost. Resin, the go-to for professional repair, merely fills a tooth rather than rebuilding it, and has a finite lifespan, often resulting in necessary replacements and high costs for patients. It is against this backdrop that Eterna has created a keratin-based material that can be added to toothpaste, enabling cost-effective and lasting enamel regeneration.

Eterna's patented keratin-based product has delivered striking results. In vitro experiments carried out on extracted tooth samples revealed a new, enamel-like layer forming directly on the tooth surface, as the material stimulates a mineralisation process. Treated samples showed hardness and mechanical strength restored to levels close to that of native, healthy enamel. Moreover, the technology has shown the capacity to reduce abrasion and even treat decay. This provides a first glimpse into what it might look like to help a tooth heal itself, instead of simply patching over damage. It is also significantly cheaper than alternatives, delivering meaningful treatment at a fraction of the cost.

Hussein Kanji, Partner at Hoxton Ventures

"Eterna is the kind of company we like to back early: powerful, defensible science with a capital-efficient route to market. Its technology has the potential to transform oral care from managing enamel loss to actually repairing it, while opening the door to broader applications in tissue and bone regeneration. Khaled and Sherif are the right scientific team to bring this from the lab and to global scale."

Gina Kirch, Founding Partner at The Venture Collective:

"Eterna is looking beyond basic healing to achieve complete tissue restoration. For too long, patients have had to settle for treatments that manage damage rather than repair it. Eterna is revolutionizing this standard of care, harnessing its patented keratin technology to help the body regenerate itself more fully than existing options allow."

Eterna's second application will build on the same patented knowledge, this time targeting bone regeneration. Today, when someone breaks a bone, soft tissue grows back into the site without resolving the underlying fragility. Medical solutions typically involve inserting a collagen membrane and hoping the bone regrows. But preliminary tests suggest Eterna's keratin-based technology could be harnessed to regenerate strong, healthy bone.

Oral health is Eterna's first commercial beachhead, with further IP in the pipeline beyond bone regeneration. The company is expanding its research and commercial teams and building relationships with oral-care companies, professional partners and consumer-health groups, with a clear focus on delivering its first commercial product in the near term. By embedding its material into products already on the market, Eterna aims to bring its sophisticated but accessible science directly to consumers.

About Eterna

Eterna Regeneratives is a UK biotechnology spin-out from King's College London, founded in 2024 by Khaled Eissa and Sherif Elsharkawy. Backed by Hoxton Ventures and The Venture Collective, Eterna is building a biomaterials platform for mineralisation and tissue regeneration, with initial applications in enamel repair and bone. Their patented platform uses keratin, derived from sheep's wool, to guide new mineral growth at the site of damage, working with the body's own chemistry beyond just protection. The company has now grown into a new lab space in Canary Wharf, where they are focused on commercialising their product, building their IP pipeline, and partnering with healthcare companies to bring their product to the mass market.

SOURCE Eterna Regeneratives Ltd

Share this article

New enhancements advance reporting precision, Method of Detection tracking, and clinical workflow efficiency

DALLAS, Sept. 17, 2026 /PRNewswire/ -- Ikonopedia, a leader in structured reporting and clinical decision support for breast imaging, today announced the release of Ikonopedia 2026.08.0, featuring significant updates aligned with BI-RADS® v2025 (6th Edition). The release was deployed the evening of September 15 and includes enhancements to Method of Detection tracking and reporting, along with additional performance improvements.

Advancing Breast Imaging Reporting

Ikonopedia 2026.08.0 incorporates updated terminology defined by the American College of Radiology (ACR) in the latest BI-RADS manual. The updates span mammography, breast ultrasound, breast MRI, and pathology workflows, helping reduce ambiguity and support more consistent reporting.

Among the terminology changes are the removal of terms such as "developing asymmetry" in mammography and "focus" in breast MRI. By incorporating the updated terminology directly into its structured reporting workflows, Ikonopedia helps radiologists seamlessly align with evolving breast imaging standards.

"BI-RADS continues to evolve, and Ikonopedia is committed to helping our customers stay aligned with the latest standards without disrupting their workflows," said Emily Crane, CEO of Ikonopedia. "This release delivers important updates while continuing to improve the efficiency and usability of the platform."

Enhancing Method of Detection Tracking

The release also expands Ikonopedia's Method of Detection (MOD) capabilities, which have been available since 2024. With BI-RADS v2025 encouraging the assignment of Method of Detection, Ikonopedia provides tools to track MOD and connect cancer outcomes with screening and clinical presentation.

Enhanced auditing and reporting capabilities allow customers to analyze Method of Detection through administrative and analytics reporting, providing greater insight into breast cancer detection and supporting quality improvement initiatives.

Additional updates include workflow, usability, and performance improvements based on ongoing customer feedback.

To request more information or to enable this feature, email the Ikonopedia Support team.

About Ikonopedia

Ikonopedia provides cloud-based structured reporting and decision support solutions for breast imaging. Designed by radiologists, Ikonopedia helps practices improve accuracy, streamline workflows, and support alignment with industry standards, ultimately enhancing patient care. For more information, visit www.ikonopedia.com.

Emily Crane

CEO

[email protected]

SOURCE Ikonopedia

Share this article

Agreement secured through channel partner Amwell significantly expands Dario's reach through its channel distribution strategy

Program for Dario's cardiometabolic suite and provider-backed care expected to launch with the customer and begin generating revenue in the first quarter of 2027

Marks the third large state health plan signed through Amwell in the past 12 months, following contracts in Arizona and Florida

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced a new contract with a leading health plan in New Jersey, one of the largest in the state representing approximately 1.5 million covered lives. The agreement was secured through Dario's strategic channel partnership with Amwell and is expected to launch and begin generating revenue in the first quarter of 2027.

The new agreement represents a significant expansion of Dario's reach into large health plan populations and further demonstrates the scalability of the Company's channel distribution strategy. As an administrative services only ("ASO") health plan, the customer provides Dario with the opportunity to access a large population of self-funded employer groups that will be able to deploy Dario's cardiometabolic solutions.

"This is exactly the type of scale we envisioned when we built our channel strategy," said Erez Raphael, Chief Executive Officer of Dario. "A single agreement gives Dario the opportunity to reach one and a half million covered lives through one of New Jersey's largest health plans, while our multi-condition platform and provider-backed care capabilities create opportunities to deliver even greater value within each employer customer relationship. Combined with DarioIQ's ability to personalize engagement at scale, this agreement brings together several growth drivers and demonstrates the compounding potential of the platform we have built."

The agreement further expands Dario's relationship with Amwell as a scalable distribution channel and stands in addition to previously secured contracts with major health insurers in Arizona and Florida. The addition of approximately 1.5 million covered lives through the New Jersey plan demonstrates the potential for channel partners to connect Dario with large payer populations while reducing reliance on a traditional direct-sales model.

Dario's integrated platform enables health plans and employers to address multiple chronic conditions through a single solution spanning diabetes, hypertension, weight management, musculoskeletal and behavioral health needs. Dario has also expanded its platform to include provider-backed clinical care, extending its capabilities from continuous digital engagement and chronic condition management through provider-led care.

About DarioHealth Corp.

DarioHealth (Nasdaq: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.

Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected launch of the program with the New Jersey health plan and the timing thereof; the expectation that the program will begin generating revenue in the first quarter of 2027; the ability of the agreement and the Company's relationship with Amwell to expand the Company's reach to covered lives and self-funded employer groups; the potential deployment of Dario's cardiometabolic solutions by such employer groups; and the scalability, growth potential and expected benefits of the Company's channel distribution strategy, platform and provider-backed care capabilities. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari

SVP Corporate Development

[email protected] 

+1-201-785-6310

Rob Halpern

SVP Marketing

[email protected] 

SOURCE DarioHealth Corp.

Share this article

Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 months

No changes to the safety sections of labeling with longer follow-up and no new safety signals identified

Approval comes four months ahead of PDUFA date

NEW YORK, Sept. 16, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for IBTROZI® (taletrectinib), a ROS1 inhibitor approved for the treatment of locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

The updated IBTROZI label now reflects updated median duration of response (DOR) for the TRUST-I study, with a median DOR of 49.7 months in TKI-naïve patients in TRUST-I, reflecting more than four years of sustained clinical benefit. This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up, confirming the safety profile.

The sNDA approval reflects a median follow-up of 51 months for patients from the TRUST-I study and incorporates an additional 14 months of data from both of the pivotal TRUST-I and TRUST-II studies as of an August 2025 data cutoff. Many patients remained on therapy for extended periods with a continued response—some for multiple years—highlighting the long-term durability and tolerability of IBTROZI and reinforcing its importance as a treatment option for advanced ROS1+ NSCLC. These data were also presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 and simultaneously published in the Journal of Clinical Oncology.

"This approval is a significant milestone for IBTROZI because this data is now part of the FDA-approved label, something physicians and patients can turn to directly," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "A median duration of response of more than four years—the longest median DOR reported for an FDA-approved ROS1 TKI—is a remarkable outcome for people living with ROS1+ NSCLC, and having it in the label means something real for patients: a clearer sense of how long they might expect to stay on treatment, and more confidence in what that path could look like at a moment when a new diagnosis can feel overwhelming. It also gives physicians additional evidence to support using IBTROZI early in a patient's care, when that choice matters most."

The U.S. FDA granted full approval to IBTROZI in June 2025 for the treatment of locally advanced or metastatic ROS1+ NSCLC across lines of therapy. IBTROZI is also approved for patients with advanced ROS1+ NSCLC in Japan, where it is marketed by Nippon Kayaku, and in China, where it is marketed by Innovent Biologics under the brand name DOVBLERON®. Additionally, the Company, along with its partner, Eisai, announced in March 2026 that the Marketing Authorisation Application (MAA) for taletrectinib was validated by the European Medicines Agency (EMA) for full approval consideration with a standard review timeline, and in June 2026 that the MAA was validated by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.

About ROS1+ NSCLC

Each year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain. The brain is also the most common site of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.

About IBTROZI

IBTROZI is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough Therapy designations for both TKI-naive and TKI-pretreated disease, the U.S. Food and Drug Administration (FDA) approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. Learn more about taletrectinib in the U.S. at IBTROZI.com. 

About the TRUST Clinical Program

The TRUST clinical program comprises three registrational studies evaluating the safety and efficacy of IBTROZI. TRUST-I (NCT04395677) and TRUST-II (NCT04919811) are Phase 2 single-arm studies evaluating IBTROZI for the treatment of adults with advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (NCT07154706) is a Phase 3 placebo-controlled study evaluating IBTROZI for the adjuvant treatment of adults with resected early-stage ROS1+ NSCLC. The study will enroll approximately 180 patients in the U.S., Canada, Europe, Japan and China. The primary endpoint is disease-free survival as determined by investigator, and the primary completion date is estimated to be in 2030. Nuvation Bio is also sponsoring TRUST-III (NCT06564324), a confirmatory randomized Phase 3 study evaluating IBTROZI versus crizotinib in 194 patients in China with advanced ROS1+ NSCLC who have not previously received ROS1 TKIs. 

U.S. Indication

IBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC).

IMPORTANT SAFETY INFORMATION FOR IBTROZI® (taletrectinib)

WARNINGS AND PRECAUTIONS

Hepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).

Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients.

Concurrent elevations in AST or ALT ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients.

Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).

ILD/pneumonitis led to dose interruption in 1.1% of patients, dose reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients.

QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner.

In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade ≥3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction each occurred in 2.8% of patients.

Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors, and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc.

Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade ≥3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients.

Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).

Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation.

Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures. 3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption occurred in 0.3% of patients.

Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can cause fetal harm when administered to a pregnant woman.

ADVERSE REACTIONS

Among patients who received IBTROZI, the most frequently reported adverse reactions (≥20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%).

The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%).

DRUG INTERACTIONS

- Strong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use.

- Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI.

OKLAHOMA CITY, Sept. 17, 2026 /PRNewswire/ -- Bank7 Corp. (NASDAQ: BSVN) (the "Company"), the parent company of Oklahoma City-based Bank7, and Century Financial Services Corporation ("Century"), the Santa Fe, New Mexico-based bank holding company for Century Bank, jointly announce today that they have entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") to which Bank7 Corp. will acquire 100% of the outstanding common stock of Century Financial Services Corporation.

"The Century team members have built an exceptional, legacy deposit franchise through a trusted, relationship-driven banking model that has served New Mexico communities for generations. We look forward to working closely together to continue building on their work," said Thomas L. Travis, President and CEO of Bank7. "This transaction extends our footprint into an attractive and neighboring Southwest market, represents a disciplined use of our excess capital, and positions the combined organization to deliver personalized, high-touch service to even more business owners and entrepreneurs — all to the benefit of our customers, communities, and shareholders."

Upon completion, the transaction would create a combined Southwest banking organization with approximately $3.3 billion in total assets, pairing Bank7's high-performing franchise with Century's long-established New Mexico deposit franchise. The Company expects the acquisition to extend its footprint into an attractive and adjacent new market while adding a stable, legacy core deposit base.

Founded in 1887, Century Bank is one of the last remaining independent banks headquartered in New Mexico and the second-largest bank headquartered in the state. Century operates eight branches across New Mexico, complemented by two loan production offices in Dallas and Houston, Texas, and serves its markets through a relationship-driven, "local-first" community banking model with the capabilities of a regional bank. As of June 30, 2026, Century Bank reported total assets of $1.36 billion, total deposits of $1.23 billion, and gross loans of $845 million.

"We believe this is a great opportunity for both banks to enhance their presence in the southwest and create a stronger more robust banking institution to benefit our customers, employees, and communities," says Max Myers, CEO of Century Bank. "We are excited about this partnership and the opportunities it will provide for everyone involved. We look forward to expanding our existing presence in Texas and working closely with the leadership team at Bank7 to facilitate a seamless transition for our customers throughout New Mexico."

Bank7 intends to retain the Century Bank name and brand image.

Strategic Rationale

- Premier legacy, core deposit franchise. Century's $1.2 billion legacy, core deposit franchise — built over more than a century of community relationships — will strengthen the combined company's funding profile.

- Attractive market extension. The acquisition expands Bank7 into New Mexico, with a heavy focus on the attractive Santa Fe market, a contiguous addition to its existing Oklahoma, Texas, and Kansas markets.

- Scarcity value. As one of the last remaining independent banks headquartered in New Mexico and the second-largest bank based in the state, Century represents a rare franchise opportunity in Santa Fe, one of the region's most attractive and resilient markets.

- Disciplined use of excess capital. The transaction deploys excess capital that Bank7 has accumulated over time into a franchise-enhancing acquisition, an enhancement the Company believes will generate stronger long-term returns than buybacks, dividends, or organic growth alone.

Transaction Structure and Process

In connection with a receivership proceeding captioned KS StateBank Corporation v Peters et al., pending in the U.S. District Court for the District of Arizona (the "Receivership Case"), the Company previously announced on September 3, 2026 that it was named the successful bidder at an auction for a 71% controlling interest in Century, which was memorialized in a Receivership Stock Purchase Agreement (the "Receivership SPA"). Immediately following the auction, the Company and Century commenced negotiations to enter into the Merger Agreement. Subject to all necessary court approvals in the Receivership Case, Century's shareholder approvals and applicable regulatory approvals, the Company intends to pursue closing the transactions contemplated under the Merger Agreement. If, for any reason, the Merger Agreement is terminated, the Company intends to pursue closing the transactions contemplated in the Receiver SPA, which remains in effect following entry into the Merger Agreement.

Under the terms of the Merger Agreement, the Company will acquire 100% of the outstanding common stock of Century. Century will merge with and into the Company, with the Company continuing as the surviving entity, and Century Bank will subsequently merge with and into Bank7. At closing, each outstanding share of Century common stock will be converted into the right to receive a pro rata portion of aggregate consideration consisting of $70 million in cash and 1,232,657 shares of Company common stock. Based on 332,683 shares of Century common stock outstanding, this would equate to $210.41 in cash and 3.7052 shares of Company common stock per Century share, and implies an aggregate transaction value of approximately $137.3 million based on the Company's 10-day average closing share price of $54.57 as of September 16, 2026. Following the merger, Century Bank will merge with and into Bank7. The Company's previously announced agreement to acquire an approximately 71% controlling interest in Century from the court-appointed receiver remains in effect, and the Company pursuing the whole company transaction as its preferred path.

Under the terms of the Merger Agreement, the Company will acquire 100% of the outstanding common stock of Century. Century will merge with and into the Company, with the Company continuing as the surviving entity, and Century Bank will subsequently merge with and into Bank7. At closing, each outstanding share of Century common stock will be converted into the right to receive a pro rata portion of aggregate consideration consisting of $70 million in cash and 1,232,657 shares of Company common stock. Based on 332,683 shares of Century common stock outstanding, this would equate to $210.41 in cash and 3.7052 shares of Company common stock per Century share, and implies an aggregate transaction value of approximately $136.9 million based on the Company's 10-day average closing share price of $54.28 as of September 15, 2026. The shares of Company common stock issued as consideration will be issued in a private placement exempt from registration under the Securities Act, and Century shareholders who are not accredited investors will receive cash in lieu of shares. The transaction is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes. Completion of the transaction is subject to approval by Century's shareholders, the receipt of all required bank regulatory approvals, and the satisfaction of customary closing conditions. Century's directors and executive officers, the receiver, and certain minority shareholders, collectively holding a substantial majority of Century's outstanding shares, have entered into voting agreements in support of the transaction. The Company's previously announced Stock Purchase Agreement with the court-appointed receiver in the receivership proceeding captioned KS StateBank Corporation v. Peters, et al., pending in the U.S. District Court for the District of Arizona, remains in full force and effect, and the Company reserves all of its rights thereunder. A whole company transaction under the Merger Agreement is the Company's preferred path, and the Company intends to pursue it in lieu of, but without waiver of, the purchase of a controlling interest. Depending on the outcome of the court process and the terms of any order entered by the Court, the Company may elect to proceed under the Stock Purchase Agreement instead. The transaction is expected to close in the fourth quarter of 2026. There can be no assurance that either transaction will be completed on the terms described, or at all.

About Bank7 Corp.

We are Bank7 Corp., a bank holding company headquartered in Oklahoma City, Oklahoma. Through our wholly-owned subsidiary, Bank7, we operate twelve locations in Oklahoma, the Dallas/Fort Worth, Texas metropolitan area and Kansas. We are focused on serving business owners and entrepreneurs by delivering fast, consistent and well-designed loan and deposit products to meet their financing needs.

About Century Bank

Established in 1887, Century Bank is a locally owned community bank with eight full-service branches throughout New Mexico and two loan production offices in Texas. Century Bank offers a wide range of quality tailored banking services to businesses and residents with active ties to the communities they serve. For more information, visit www.mycenturybank.com/.

Advisors

Keefe, Bruyette & Woods, A Stifel Company, is serving as financial advisor to the Company. Nelson Mullins Riley & Scarborough LLP, is serving as legal counsel to the Company. MJC Partners is serving as financial advisor to Century. Otteson Shapiro LLP is serving as legal counsel to Century.

Forward-Looking Statements

This press release and oral statements made regarding the subject of this press release contain forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the proposed merger with Century, the expected terms, timing, and benefits of the transaction, and the anticipated financial and strategic impact on the combined organization.

ComNet Communications Appoints Janna Valencia as Chief Revenue Officer

BETHEL, Conn., Sept. 17, 2026 /PRNewswire/ -- ComNet Communications ("ComNet"), a leading nationwide provider of low voltage infrastructure solutions, serving blue-chip clients across e-commerce, industrial, office, and technology environments, including data centers, announced the appointment of Janna Valencia as its new Chief Revenue Officer. Janna brings extensive industry experience and will lead ComNet's revenue strategy and growth initiatives as the company continues to expand its national presence and strengthen its customer relationships.

Janna joins ComNet from BlackBox, a global leader in digital infrastructure solutions. She has more than twenty years of experience with additional significant leadership roles at IBM and Kyndryl, where she was responsible for large national sales and delivery teams. Her expertise covers a wide range of customer segments, including data centers, retail, CPG, travel and transportation, hospitality, airports, and the public sector.

Chief Executive Officer Glenn Wagner said, "We are thrilled to welcome Janna to ComNet and are excited by her proven ability to recruit, develop, and lead teams with a collaborative leadership style. Specifically, we expect Janna will be instrumental in building out specialized vertical focused teams to help even better serve our existing and future customers as we deploy our strategic plans."

Janna added, "I am excited to work alongside Glenn and the entrepreneurial leadership team at ComNet that is focused on delivering customer success. ComNet is a highly regarded national player in the digital infrastructure and structured cabling sector, and I am thrilled to be joining at this exciting time and help drive continued growth."

About ComNet Communications

ComNet Communications is a national provider of network infrastructure installation services headquartered in Bethel, Connecticut. The company designs, installs, and supports mission-critical structured cabling, audiovisual, and security systems for enterprise clients across industries including healthcare, data centers, distribution, corporate campuses, and higher education. ComNet has built its reputation on safety, quality, and service excellence, delivering reliable solutions to Fortune 500 companies, national enterprises, and regional businesses.

Contact:

Christina Maldonado, LLYC

[email protected]

914-393-6822

SOURCE ComNet Communications

Share this article

ST. PETERSBURG, Fla., Sept. 17, 2026 /PRNewswire/ -- Squaremouth, the nation's largest travel insurance comparison platform, announces the expansion of its partnership with Trawick International Travel Insurance, providing travelers with access to additional travel insurance coverage options on Squaremouth.com.

"At Squaremouth, we're focused on bringing together the best travel insurance options available, so travelers can find coverage that matches the type of trip they're taking," shared Rupa Mehta, CEO of Squaremouth. "Adding these products to our marketplace ensures we are delivering on that promise."

Trawick Pathway Plus and Trawick Pathway Premium, part of Trawick's new suite of products, complement the existing Trawick products on Squaremouth.com, including Trawick Pathway Essential, Trawick Safe Travels Annual Select, Trawick Safe Travels Annual Preferred, and Trawick Safe Travels Annual Prime. Available for U.S. residents in all states, the two new plans are ideal for luxury travel or longer vacations, with high trip cost allowances and coverage for up to 90 days of travel.

"We're thrilled to expand our Pathway suite with Pathway Premium and Pathway Plus and bring these new options to travelers through Squaremouth," said Bailey Foster, Senior Vice President of Travel Insurance at Trawick International. "Squaremouth has been an incredible partner in helping travelers compare coverage and find the right protection for their trips, and we're excited to continue growing our relationship. Adding these plans gives travelers even more choice and flexibility, while building on the strong Pathway lineup they already know and trust."

Trawick International Pathway Plus and Pathway Premium

Launched on Squaremouth: August 27, 2026

Pathway Plus Key Features and Benefits:

- Emergency Medical: $100,000 per person (Primary)

- Medical Evacuation: $350,000 per person

- Trip Cancellation: 100% of the insured trip cost, up to $50,000

- Trip Interruption: 125% of the insured trip cost

- Travel Delay: $1,000 per person, with a $200 daily limit

- Baggage and Personal Effects: $1,000 per person

- Baggage Delay: $300 per person

- 24/7 Emergency Assistance: Included

Optional Upgrades:

- Adventure/Extreme Sports Upgrade: Provides coverage for eligible adventure and extreme sports. Not available to residents of MA, MN, MO, MT, NY, OR, or WA.

- Flight-Only AD&D: $25,000 optional coverage.

- Rental Car Damage: $50,000 optional coverage, subject to state availability.

Pathway Premium Key Features and Benefits:

- Emergency Medical: $200,000 per person (Primary)

- Medical Evacuation: $1,000,000 per person

- Trip Cancellation: 100% of the insured trip cost, up to $100,000

- Trip Interruption: 150% of the insured trip cost

- Travel Delay: $2,000 per person, with a $300 daily limit

- Baggage and Personal Effects: $2,000 per person

- Baggage Delay: $500 per person

- 24/7 Emergency Assistance: Included

Optional Upgrades:

- Adventure/Extreme Sports Upgrade: Available with coverage; eligibility varies by state.

- Rental Car Damage: $50,000 optional coverage, subject to state availability.

- 75% CFAR Coverage: Available if purchased within 21 days of the initial trip deposit, subject to plan terms and eligibility requirements.

- 75% IFAR Coverage: Available if purchased within 21 days of the initial trip deposit, subject to plan terms and eligibility requirements.

To learn more about all Trawick International plans on Squaremouth.com and to compare options, click here.

About Squaremouth 

For over 20 years, Squaremouth has helped more than 4.4 million travelers quote, compare, and purchase travel insurance online. Renowned for its award-winning customer service, commitment to transparency, and unbiased approach, Squaremouth has been a leader in travel insurance comparison since 2003. As America's largest travel insurance marketplace, Squaremouth.com features more providers and plans than any other platform.

Contact

Lauren McCormick

Manager, Public Relations & Social Strategy

[email protected]

SOURCE Squaremouth

Share this article

GREENSBURG, Pa., Sept. 17, 2026 /PRNewswire/ -- FirstEnergy Pennsylvania Electric Company ("FE PA" or the "Company"), a subsidiary of FirstEnergy Corp., today announced an offer to exchange up to (i) $300 million aggregate principal amount of its outstanding unregistered 4.150% Senior Notes due 2028 and (ii) $550 million aggregate principal amount of its outstanding unregistered 4.550% Senior Notes due 2031 (collectively, the "Outstanding Notes") for a like principal amount of each of the Company's (i) 4.150% Senior Notes due 2028 and (ii) 4.550% Senior Notes due 2031 (collectively, the "New Notes"), in each case registered under the Securities Act of 1933, as amended.

The exchange offer will expire at 5:00 p.m., New York City time, on October 16, 2026, unless extended. Tenders of Outstanding Notes must be made before the exchange offer expires and may be withdrawn any time prior to the expiration of the exchange offer. The exchange offer is being made to satisfy the Company's obligations under registration rights agreements entered into in connection with the issuance of the Outstanding Notes and does not represent a new financing transaction.

The terms of the exchange offer are set forth in a prospectus dated September 17, 2026. Copies of the prospectus and the other exchange offer documents may be obtained from the exchange agent:

U.S. Bank Trust Company, National Association, as Exchange Agent

By Mail or in Person

U.S. Bank Trust Company, National Association

Attn: Corporate Actions

111 Fillmore Avenue E

St. Paul, MN 55107-1402

For Email or Facsimile Transmission (for Eligible Institutions Only):

Email: [email protected]

Facsimile: (651) 466-7367

For Information and to Confirm by Telephone:

(800) 934-6802

This news release is for informational purposes only and is neither an offer to buy or sell nor a solicitation of an offer to buy or sell any Outstanding Notes or New Notes. The exchange offer is being made only pursuant to the exchange offer prospectus, which is being distributed to holders of the Outstanding Notes and has been filed with the Securities and Exchange Commission as part of the Company's Registration Statement on Form S-4 (File No. 333- 298694), which was declared effective on September 15, 2026.

FE PA is known locally as Penn Power, Penelec, Met-Ed and West Penn Power.

Penn Power serves approximately 173,000 customers in all or parts of Allegheny, Beaver, Butler, Crawford, Lawrence and Mercer counties in western Pennsylvania. Follow Penn Power on X @Penn_Power, on Facebook at facebook.com/PennPower, and online at pennpower.com.

Penelec serves approximately 597,000 customers within 17,600 square miles of northern and central Pennsylvania and western New York. Follow Penelec on X @Penelec and on Facebook at facebook.com/PenelecElectric.

Met-Ed serves approximately 592,000 customers within 3,300 square miles of eastern and southeastern Pennsylvania. Follow Met-Ed on X @Met Ed and on Facebook at facebook.com/MetEdElectric.

West Penn Power serves approximately 746,000 customers in 24 counties within central and southwestern Pennsylvania. Follow West Penn on X @W_Penn_Power and on Facebook at facebook.com/WestPennPower.

FirstEnergy is dedicated to integrity, safety, reliability and operational excellence. Its electric distribution companies form one of the nation's largest investor-owned electric systems, serving customers in Ohio, Pennsylvania, New Jersey, West Virginia, Maryland and New York. FirstEnergy's transmission subsidiaries operate approximately 24,000 miles of transmission lines that connect the Midwest and Mid-Atlantic regions. Follow FirstEnergy on X @FirstEnergyCorp or online at firstenergycorp.com.

Discussion of Forward-Looking Statements About FE PA

Statements in this document regarding FE PA that are not historical facts are "forward-looking statements" that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company's business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, FE PA undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see FE PA's Securities and Exchange Commission filings, including, but not limited to, the risk factors and Cautionary Note Regarding Forward-Looking Statements set forth in these filings and any updates to such risk factors and Cautionary Note Regarding Forward-Looking Statements contained in any subsequent reports on Form 10-K, Form 10-Q or Form 8-K.

SOURCE FirstEnergy Corp.

Share this article

Proposed Rule Could Take Effect as Early as December 2026 or January 2027 and Would Rapidly Phase Out Artificial Stone Containing More Than 1% Crystalline Silica

NOVATO, Calif., Sept. 17, 2026 /PRNewswire/ -- Brayton Purcell LLP today announced that California's Division of Occupational Safety and Health (Cal/OSHA) has released a draft emergency regulation that would prohibit the manufacture and fabrication of artificial stone containing more than 1% crystalline silica, a major milestone in the state's response to the ongoing silicosis epidemic affecting countertop fabrication workers.

The proposed regulation follows years of scientific research, medical evidence, and advocacy by physicians, workers, and families impacted by artificial stone silicosis. Earlier this year, the California Occupational Safety and Health Standards Board granted a petition submitted by the more than 600 physicians of the Western Occupational and Environmental Medical Association (WOEMA), urging the state to prohibit the fabrication and installation of artificial stone because of its severe occupational health risks.

Artificial stone, commonly used for kitchen and bathroom countertops, contains at least 90% crystalline silica by weight. Fabrication activities such as cutting, grinding, polishing, and edging release airborne nano-sized, high-surface area respirable crystalline silica dust. Medical and scientific research has increasingly linked exposure to artificial stone dust with accelerated silicosis, a progressive, irreversible, and fatal lung disease.

Cal/OSHA is accepting public comments on the draft emergency regulation through Sept. 30, 2026. Following the public comment period, the proposal will be considered by the Cal/OSHA Standards Board. If approved at the Board's October or November meeting, the emergency regulation could become effective as early as December 2026 or January 2027.

The proposal establishes a two-stage implementation process:

- Sixty days after the emergency regulation becomes effective, employers would no longer be permitted to purchase new artificial stone containing more than 1% crystalline silica for fabrication or manufacture.

- Employers would be allowed to continue fabricating inventory they purchased, contracted for, or possessed before the regulation's effective date during a limited transition period.

- All manufacture and fabrication of artificial stone containing more than 1% crystalline silica would be prohibited 180 days after the regulation becomes effective, regardless of when the material was acquired.

As a practical matter, if the regulation becomes effective in December 2026 or January 2027, California fabrication shops would have approximately six months to work through existing inventory before the prohibition is fully implemented.

"The release of this draft emergency regulation is a landmark moment in California's effort to address a devastating occupational disease that has affected hundreds of workers and their families," said James Nevin, partner at Brayton Purcell LLP, whose firm represents over 900 artificial stone silicosis clients throughout the U.S. "After reviewing scientific evidence, Cal/OSHA concluded that artificial stone is inherently dangerous and uniquely toxic. The agency's proposal reflects a growing recognition that existing control measures are not sufficient to prevent workers from developing silicosis. We commend Cal/OSHA for taking this important step and encourage the Standards Board to move quickly to finalize these protections."

California has documented hundreds of confirmed silicosis cases among countertop fabrication workers (644 as of today), many of whom developed disease after relatively short periods of exposure. Researchers and regulators have found that artificial stone poses hazards distinct from natural stone products because of its exceptionally high silica content, the presence of nano-sized, high-surface area particles generated during fabrication, and the additional uniquely toxic blend of resins, dyes, glues and heavy metals incorporated into the material.

The proposed regulation also reflects developments in other jurisdictions. Australia implemented a nationwide prohibition on artificial stone in 2024 after concluding that enforcement efforts and engineering controls could not adequately protect workers from crystalline silica exposure. Australian regulators reported that safer alternative countertop materials were, and have remained, widely available and that the transition away from artificial stone did not result in economic disruption.

"Workers and families across California have lived with the consequences of this disease for far too long," Nevin said. "The proposed regulation provides a clear pathway toward reducing future cases of artificial stone silicosis while allowing businesses time to transition to safer alternatives that are already available in the marketplace."

About Brayton Purcell LLP

Brayton Purcell LLP is a California-based law firm with a decades-long history of representing individuals and families affected by occupational diseases and toxic exposures. The firm has handled litigation involving silica-related illnesses, asbestos-related diseases, and other toxic exposure claims throughout California and the United States.

Media Contact

Nolan Lowry

Chief Marketing Officer

[email protected]

415-399-3701

www.braytonlaw.com

Brayton Purcell LLP

SOURCE Brayton Purcell LLP

Share this article